<li>afatinib<p>simvastatin increases levels of afatinib by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Reduce afatinib daily dose by 10 mg if not tolerated when coadministered with P-gp inhibitors.</p></li><li>amiodarone<p>amiodarone increases toxicity of simvastatin by decreasing metabolism. Avoid or Use Alternate Drug. Do not exceed simvastatin 20 mg daily when given concurrently. Potential for increased risk of myopathy/rhabdomyolysis.</p></li><li>amlodipine<p>amlodipine increases levels of simvastatin by Other (see comment). Avoid or Use Alternate Drug. 
Comment: Benefits of combination therapy should be carefully weighed against the potential risks of combination. Potential for increased risk of myopathy/rhabdomyolysis. Limit simvastatin dose to no more than 20 mg/day when used concurrently.</p></li><li>aprepitant<p>aprepitant will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>armodafinil<p>armodafinil will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>artemether/lumefantrine<p>artemether/lumefantrine will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>bezafibrate<p>bezafibrate, simvastatin.
Either increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Increased risk of rhabdomyolysis.</p></li><li>bosentan<p>bosentan will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>bosutinib<p>simvastatin increases levels of bosutinib by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug.</p></li><li>butabarbital<p>butabarbital will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>butalbital<p>butalbital will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>carbamazepine<p>carbamazepine will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>cimetidine<p>cimetidine will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>clobetasone<p>clobetasone will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>colchicine<p>colchicine, simvastatin.
Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased risk of rhabdomyolysis (incl a fatality).</p></li><li>conivaptan<p>conivaptan will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>darifenacin<p>darifenacin will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>dasatinib<p>dasatinib will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>dexamethasone<p>dexamethasone will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>diltiazem<p>diltiazem will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Benefits of combination therapy should be carefully weighed against the potential risks of combination. Limit simvastatin dose to no more than 10 mg/day when used concurrently.</p></li><li>eltrombopag<p>eltrombopag will increase the level or effect of simvastatin by  Other (see comment). Avoid or Use Alternate Drug. OATP1B1 inhibitors may increase risk of myopathy</p></li><li>eluxadoline<p>simvastatin increases levels of eluxadoline by decreasing metabolism. Avoid or Use Alternate Drug. Decrease eluxadoline dose to 75 mg PO BID if coadministered with OATP1B1 inhibitors. .</p></li><li>eslicarbazepine acetate<p>eslicarbazepine acetate will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>ethotoin<p>ethotoin will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>etravirine<p>etravirine will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>eucalyptus<p>eucalyptus will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>fenofibrate<p>fenofibrate, simvastatin.
Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Fenofibrate may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs.</p></li><li>fenofibrate micronized<p>fenofibrate micronized, simvastatin.
Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Fenofibrate may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs.</p></li><li>fenofibric acid<p>fenofibric acid, simvastatin.
Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Fenofibrate may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs.</p></li><li>fluconazole<p>fluconazole will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>fosphenytoin<p>fosphenytoin will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>grapefruit<p>grapefruit will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid consuming large quantities of grapefruit or juice (ie, &gt;1 quart/day)</p></li><li>griseofulvin<p>griseofulvin will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>hexobarbital<p>hexobarbital will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>hydrocortisone<p>hydrocortisone will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>isoniazid<p>isoniazid will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>ivacaftor<p>ivacaftor increases levels of simvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Ivacaftor and its M1 metabolite has the potential to inhibit CYP3A4, may significantly increase systemic exposure to 3A4 substrates.<span><br><br></span>ivacaftor increases levels of simvastatin by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Ivacaftor and its M1 metabolite has the potential to inhibit P-gp, may significantly increase systemic exposure to P-gp substrates.</p></li><li>lapatinib<p>lapatinib will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>lomitapide<p>lomitapide increases levels of simvastatin by decreasing metabolism. Avoid or Use Alternate Drug. Reduce simvastatin dose by 50% when initiating lomitapide dosing.</p></li><li>lumefantrine<p>lumefantrine will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>marijuana<p>marijuana will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>mephobarbital<p>mephobarbital will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>mesterolone<p>mesterolone increases toxicity of simvastatin by decreasing metabolism. Avoid or Use Alternate Drug. Risk of rhabdomyolysis (theoretical interaction based on case reports of combination of danazol and &gt;20 mg/day lovastatin).</p></li><li>methylprednisolone<p>methylprednisolone will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>metronidazole<p>metronidazole will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>mibefradil<p>mibefradil will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>miconazole vaginal<p>miconazole vaginal will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>modafinil<p>modafinil will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>nafcillin<p>nafcillin will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>nevirapine<p>nevirapine will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>niacin<p>niacin, simvastatin.
Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased risk of rhabdomyolysis (&gt;1 g/day niacin).</p></li><li>nifedipine<p>nifedipine will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>nilotinib<p>nilotinib will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>oxcarbazepine<p>oxcarbazepine will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>oxiconazole<p>oxiconazole will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>pentobarbital<p>pentobarbital will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>phenobarbital<p>phenobarbital will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>phenytoin<p>phenytoin will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>pomalidomide<p>simvastatin increases levels of pomalidomide by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug.</p></li><li>prednisolone<p>prednisolone will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>prednisone<p>prednisone will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>primidone<p>primidone will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>quinupristin/dalfopristin<p>quinupristin/dalfopristin will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>ranolazine<p>ranolazine increases levels of simvastatin by Other (see comment). Avoid or Use Alternate Drug. 
Comment: Benefits of combination therapy should be carefully weighed against the potential risks of combination. Potential for increased risk of myopathy/rhabdomyolysis. Limit simvastatin dose to no more than 20 mg/day when used concurrently. .</p></li><li>rifabutin<p>rifabutin will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>rifampin<p>rifampin will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>rifapentine<p>rifapentine will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>riociguat<p>simvastatin will increase the level or effect of riociguat by  decreasing metabolism. Avoid or Use Alternate Drug. Coadministration of riociguat (substrate of CYP isoenzymes 1A1, 2C8, 3A, 2J2) with strong CYP inhibitors may require a decreased initial dose of 0.5 mg PO TID; monitor for signs of hypotension and reduce dose if needed</p></li><li>rufinamide<p>rufinamide will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>secobarbital<p>secobarbital will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>sildenafil<p>sildenafil increases toxicity of simvastatin by Other (see comment). Avoid or Use Alternate Drug. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>sitaxentan<p>sitaxentan will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>st john's wort<p>st john's wort will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>topiramate<p>topiramate will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>troglitazone<p>troglitazone will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>troleandomycin<p>troleandomycin will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>verapamil<p>verapamil will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Do not exceed simvastatin 10 mg daily when given concurrently. Potential for increased risk of myopathy/rhabdomyolysis.</p></li><li>voriconazole<p>voriconazole will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Simvastatin prescribing information recommends a reduced simvastatin dose be considered when coadministered with voriconazole to reduce the risk of myopathy, including rhabdomyolysis</p></li><li>zafirlukast<p>zafirlukast will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li>